Rare Diseases, Drug Development, and AIDS: The Impact of the Orphan Drug Act

Milbank Quarterly - United Kingdom
doi 10.2307/3350258
Full Text
Abstract

Available in full text

Date
Authors
Publisher

JSTOR

Related search

Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering—A Cross-Sectional Analysis

Oncologist
Cancer ResearchMedicineOncology
2016English

The Effect of the Orphan Drug Development Support Program.

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
1999English

Examining the Target Population of Orphan Drugs: Are Drugs Exceeding the Intended Purposes of the Orphan Drug Act?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The Current Status of Orphan Drug Development in Europe and the US

Intractable and Rare Diseases Research
Medicine
2014English

Drug Development in Pemphigoid Diseases

Acta Dermato-Venereologica
DermatologyMedicine
2020English

Drug Development to Protozoan Diseases

Open Medicinal Chemistry Journal
Drug DiscoveryMolecular MedicinePharmacologyPharmaceutical Science
2011English

Time to Revisit the Orphan Drug Law

European Journal of Clinical Pharmacology
MedicinePharmacology
2011English

Review of Drug Quality and Security Act of 2013: The Drug Supply Chain Security Act (DSCSA)

INNOVATIONS in pharmacy
2016English

Orphan Drug Development in China ‒ Turning Challenges Into Opportunities

Intractable and Rare Diseases Research
Medicine
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy